Elmakaty Ibrahim, Saglio Giuseppe, Al-Khabori Murtadha, Elsayed Abdelrahman, Elsayed Basant, Elmarasi Mohamed, Elsabagh Ahmed Adel, Alshurafa Awni, Ali Elrazi, Yassin Mohamed
College of Medicine, QU Health, Qatar University, Doha P.O. Box 2713, Qatar.
Department of Clinical and Biological Sciences, University of Turin, 10124 Turin, Italy.
Cancers (Basel). 2024 Feb 12;16(4):754. doi: 10.3390/cancers16040754.
Hematopoietic stem cell transplantation (HSCT) for chronic myeloid leukemia (CML) patients has transitioned from the standard of care to a treatment option limited to those with unsatisfactory tyrosine kinase inhibitor (TKI) responses and advanced disease stages. In recent years, the threshold for undergoing HSCT has increased. Most CML patients now have life expectancies comparable to the general population, and therefore, the goal of therapy is shifting toward achieving treatment-free remission (TFR). While TKI discontinuation trials in CML show potential for achieving TFR, relapse risk is high, affirming allogeneic HSCT as the sole curative treatment. HSCT should be incorporated into treatment algorithms from the time of diagnosis and, in some patients, evaluated as soon as possible. In this review, we will look at some of the recent advances in HSCT, as well as its indication in the era of aiming for TFR in the presence of TKIs in CML.
慢性粒细胞白血病（CML）患者的造血干细胞移植（HSCT）已从标准治疗转变为仅限于酪氨酸激酶抑制剂（TKI）反应不佳和疾病晚期患者的治疗选择。近年来，接受HSCT的门槛有所提高。现在大多数CML患者的预期寿命与普通人群相当，因此，治疗目标正转向实现无治疗缓解（TFR）。虽然CML的TKI停药试验显示出实现TFR的潜力，但复发风险很高，这肯定了异基因HSCT是唯一的治愈性治疗方法。HSCT应从诊断时起纳入治疗方案，对于一些患者，应尽快进行评估。在本综述中，我们将探讨HSCT的一些最新进展，以及在CML存在TKI的情况下，其在旨在实现TFR时代的适应症。
